Abstract:Introduction Agitation is reported in up to 70% of individuals with Alzheimer's disease (AD) and is characterized by emotional distress, aggressive behaviors, disruptive irritability and disinhibition. Agitation is associated with increased caregiver burden, decreased functioning, accelerated cognitive decline, earlier nursing home placement, and increased mortality. AXS-05 (dextromethorphan-bupropion) is a novel, oral NMDA receptor antagonist and sigma-1 receptor agonist approved for the treatment of major depressive disorder and under evaluation for Alzheimer's disease-related agitation (ADA). Methods ACCORD (Assessing Clinical Outcomes in Alzheimer's Disease Agitation; NCT04797715) was a Phase 3, randomized, discontinuation, double-blind, placebo-controlled, multi-center trial to evaluate efficacy and safety of AXS-05 in individuals with ADA. Participants with a diagnosis of probable AD and clinically meaningful agitation were enrolled into a 9-week, open-label period during which they were treated with AXS-05 and monitored for sustained clinical response defined as a ≥30% improvement from baseline in the Cohen Mansfield Agitation Inventory (CMAI) total score and improvement on the Patient Global Impression of Change (PGI-C; score of ≤3) that were both maintained for at least 4 consecutive weeks. Participants who experienced a sustained clinical response during the open-label period were then randomized (1:1) to continue treatment with AXS-05 or placebo in a double-blind fashion for up to 26 weeks. Treatment was continued until either a relapse of agitation symptoms or the end of the double-blind period, whichever occurred first. The primary endpoint in the study was time from randomization to relapse of agitation. The key secondary endpoint was the percentage of participants who relapsed. Results 178 individuals were enrolled into the open-label period and treated with AXS-05 (mean CMAI total score at baseline = 70.9). Statistically significant improvement on the CMAI was seen with open-label AXS-05 treatment at all timepoints starting at Week 1 (P<.001) with mean reductions from baseline of 6.7 points at Week 1 and 20.6 points at Week 5 (P<.001). In the randomized discontinuation phase of the trial, 108 participants were randomized to continue AXS-05 (n=53) or switched to placebo (n=55). AXS-05 met the primary endpoint by substantially delaying the time to relapse of agitation symptoms as compared to placebo, with a hazard ratio for time to relapse of 0.275 (P=.014), representing a 3.6-fold lower risk of relapse compared to placebo. AXS-05 also met the key secondary endpoint of relapse prevention (7.5% relapse incidence rate for AXS-05; 25.9% for placebo, P=.018). The rates of adverse events observed in the double-blind period were 28.3% AXS-05, 22.2% placebo. Discontinuations due to adverse events were 0% AXS-05, 1.9% placebo. There was no evidence of cognitive decline for participants treated with AXS-05. AXS-05 was not associated with sedation. Conclusions ACCORD met its primary outcome as treatment with AXS-05 substantially reduced the risk of relapse and was generally well-tolerated for participants who achieved sustained clinical response in the preceding open label treatment period. These data support the continued development of AXS-05 as an efficacious and safe novel treatment for ADA.

Safety, Tolerability, and Pharmacokinetic Profile of the Low‐Impact Ampakine CX1739 in Young Healthy Volunteers

Preclinical characterization of a water-soluble low-impact ampakine prodrug, CX1942 and its active moiety, CX1763

Antidepressant-Like Effects of CX717, a Positive Allosteric Modulator of AMPA Receptors

High impact AMPAkines induce a Gq-protein coupled endoplasmic calcium release in cortical neurons: a possible mechanism for explaining the toxicity of high impact AMPAkines

High Impact AMPAkines Induce a Gq‐Protein Coupled Endoplasmic Calcium Release in Cortical Neurons: A Possible Mechanism for Explaining the Toxicity of High Impact AMPAkines

Novel α‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazole‐propionic acid receptor (AMPAR) potentiator LT‐102: A promising therapeutic agent for treating cognitive impairment associated with schizophrenia

First-In-Human Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of AZP2006, A Synthetic Compound for the Treatment of Alzheimer's Disease and Related Diseases

Safety, tolerability, and pharmacokinetics of KNS-760704 (dexpramipexole) in healthy adult subjects

Selective Enhancement of the Interneuron Network and Gamma-Band Power via GluN2C/GluN2D NMDA Receptor Potentiation

The Ampakine CX717 Has a Rapid, but Short-Lasting Antidepressant-Like Activity in the Rat

Concentration-QTc Relationship from a Single Ascending Dose Study of ANAVEX3-71, a Novel Sigma-1 Receptor and Allosteric M1 Muscarinic Receptor Agonist in Development for the Treatment of Frontotemporal Dementia, Schizophrenia, and Alzheimer's Disease

Phase 1 randomized study on the safety, tolerability, and pharmacodynamic cognitive and electrophysiological effects of a dopamine D1 receptor positive allosteric modulator in patients with schizophrenia

Dalzanemdor (SAGE-718), a novel, investigational N-methyl-D-aspartate receptor positive allosteric modulator: Safety, tolerability, and clinical pharmacology in randomized dose-finding studies in healthy participants and an open-label study in participants with Huntington's disease

Enhancement of Glutamate Uptake as Novel Antiseizure Approach: Preclinical Proof of Concept

Clinical pharmacology and tolerability of REC‐994, a redox‐cycling nitroxide compound, in randomized phase 1 dose‐finding studies

Preliminary pharmacokinetics and in vivo studies indicate analgesic and stress mitigation effects of a novel NMDA receptor modulator

Synthesis of [11C]BIIB104, an α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic-Acid-Positive Allosteric Modulator, and Evaluation of the Bio-Distribution in Non-Human Primate Brains Using Positron Emission Tomography

Positive AMPA Receptor Modulation Rapidly Stimulates BDNF Release and Increases Dendritic Mrna Translation

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of PF-06751979, a Potent and Selective Oral BACE1 Inhibitor: Results from Phase I Studies in Healthy Adults and Healthy Older Subjects

Assessing the Effects of Thiazole-Carboxamide Derivatives on the Biophysical Properties of AMPA Receptor Complexes as a Potential Neuroprotective Agent

Efficacy and Safety Of AXS-05 in Agitation Associated with Alzheimer's Disease: Results From ACCORD, a Phase 3, Double-Blind, Placebo-Controlled, Relapse Prevention Trial